Overview

A Study of BBI608 in Adult Patients With Advanced Malignancies

Status:
Completed
Trial end date:
2015-08-06
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc